Skip to main content

Our platform

Our proprietary platform is GMP-ready and sets a new standard in cell and gene therapy.
We use a non-viral delivery system to harness macropinocytosis - a natural cellular uptake process - for precise and secure delivery of gene-editing technologies.

Cells in suspension

1. Patient cells

Add delivery complex

2. Add gene editing complex

Done

3. Done

Quick facts

Non-viral delivery

Natural uptake mechanism

High gene editing efficiency

High cell viability

Excellent intrinsic safety

Simple implementation

Low manufacturing costs

High scalability

R&D pipeline

Opportunities

CAR-T

CRISPR/Cas9

Base editors

Prime editors

We’re supported by

Funding providers-logos